p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma

Journal of Clinical Oncology

Volumn 32, Issue 35, 2014, Pages 3930-3938

  Chung, Christine H ^a   Zhang, Qiang ^b   Kong, Christina S ^c   Harris, Jonathan ^b   Fertig, Elana J ^a   Harari, Paul M ^e   Wang, Dian ^f   Redmond, Kevin P ^g   Shenouda, George ⁱ   Trotti, Andy ^j   Raben, David ^k   Gillison, Maura L ^h   Jordan, Richard C ^d   Le, Quynh Thu ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; PROTEIN P16; MONOCLONAL ANTIBODY; P16 PROTEIN, HUMAN; TAXOID; TUMOR MARKER; TUMOR PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH STATUS; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; NONOROPHARYNGEAL HEAD AND NECK SQUAMOUS CELL CARCINOMA; OROPHARYNX; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; WART VIRUS; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; METABOLISM; MORTALITY; PAPILLOMAVIRIDAE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SMOKING; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CETUXIMAB; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SMOKING; TAXOIDS; TREATMENT OUTCOME;

EID: 84915733201     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.5228     Document Type: Article

References (31)

1. Maier H, Dietz A, Gewelke U, et al: Tobacco and alcohol and the risk of head and neck cancer. Clin Investig 70:320-327, 1992
2. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407-420, 2008
3. Poling JS, Ma XJ, Bui S, et al: Human papillomavirus (HPV) status of non-tobacco related squamous cell carcinomas of the lateral tongue. Oral Oncol 50:306-310, 2014
4. Chaturvedi AK, Engels EA, Pfeiffer RM, et al: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29:4294-4301, 2011
5. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
6. Rischin D, Young RJ, Fisher R, et al: Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 28:4142-4148, 2010
7. Lingen MW, Xiao W, Schmitt A, et al: Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol 49:1-8, 2013
8. Lee SY, Cho NH, Choi EC, et al: Is human papillomavirus a causative factor of glottic cancer? J Voice 25:770-774, 2011
9. Shi W, Kato H, Perez-Ordonez B, et al: Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 27:6213-6221, 2009
10. Jordan RC, Lingen MW, Perez-Ordonez B, et al: Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945-954, 2012
11. Rietbergen MM, Brakenhoff RH, Bloemena E, et al: Human papillomavirus detection and comorbidity: Critical issues in selection of patients with oropharyngeal cancer for treatment de-escalation trials. Ann Oncol 24:2740-2745, 2013
12. Posner MR, Lorch JH, Goloubeva O, et al: Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol 22:1071-1077, 2011
13. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
14. Dyson N, Howley PM, Münger K, et al: The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934-937, 1989
15. Münger K, Werness BA, Dyson N, et al: Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 8:4099-4105, 1989
16. Parry D, Bates S, Mann DJ, et al: Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J 14:503-511, 1995
17. Andl T, Kahn T, Pfuhl A, et al: Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5-13, 1998
18. Harari PM, Harris J, Kies MS, et al: Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). J Clin Oncol 32:2486-2495, 2014
19. Ang KK, Zhang Q, Rosenthal DI, et al: A randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940-2950, 2014
20. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:467-481, 1958
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
22. Cox DR: Regression model and life-tables. J R Stat Soc Series B 34:187-202, 1972
23. Thavaraj S, Stokes A, Guerra E, et al: Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol 64:308-312, 2011
24. Hayes DN, Grandis JR, El-Naggar AK: The Cancer Genome Atlas: Integrated analysis of genome alterations in squamous cell carcinoma of the head and neck. J Clin Oncol 31:365s, 2013 (suppl 15s; abstr 6009)
25. Montebugnoli L, Cervellati F, Cocchi R, et al: Immunohistochemical expression of p16(INK4A) protein as a helpful marker of a subset of potentially malignant oral epithelial lesions: Study on a series with long-term follow-up. Histopathology 57:528-534, 2010
26. Queiroz AB, Focchi G, Dobo C, et al: Expression of p27, p21(WAF/Cip1), and p16(INK4a) in normal oral epithelium, oral squamous papilloma, and oral squamous cell carcinoma. Anticancer Res 30: 2799-2803, 2010
27. Patel K, Ariyaratnam S, Sloan P, et al: Oral tonsils (ectopic oral tonsillar tissue). Dent Update 31:291-292, 2004
28. Mogi K: Ectopic tonsillar tissue in the mucosa of the floor of the mouth simulating a benign tumour: Case report. Aust Dent J 36:456-458, 1991
29. Lim AM, Do H, Young RJ, et al: Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int J Cancer 135:887-895, 2014
30. Harris SL, Thorne LB, Seaman WT, et al: Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck 33:1622-1627, 2011
31. Dok R, Kalev P, Van Limbergen EJ, et al: P16INK4a impairs homologous recombinationmediated DNA repair in human papillomaviruspositive head and neck tumors. Cancer Res 74:1739-1751, 2014